By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Boehringer Ingelheim Corporation 

P.O. Box 368
900 Ridgebury Road
Ridgefield  Connecticut  06877-0368  U.S.A.
Phone: 203-798-99-88 Fax: 203-791-62-34


Company News
Boehringer Ingelheim Release: Lung Cancer Experts Call For Improved EGFR Mutation Testing To Allow All Eligible NSCLC Patients Access To Personalised Treatment 11/30/2015 1:45:19 PM
Boehringer Ingelheim Release: Praxbind (Idarucizumab) Approved In European Union For The Specific Reversal Of Pradaxa (Dabigatran Etexilate) 11/30/2015 1:43:15 PM
Boehringer Ingelheim And Eli Lilly Canada Inc. (LLY) Release: Health Canada Approves JARDIANCE (empagliflozin) Tablets For Adults With Type 2 Diabetes 11/30/2015 6:22:02 AM
Boehringer Ingelheim Release: FDA Approves Pradaxa (dabigatran etexilate mesylate) For Prophylaxis Of Deep Venous Thrombosis (DVT) And Pulmonary Embolism (PE) After Hip Replacement Surgery 11/23/2015 9:24:39 AM
Boehringer Ingelheim Awarded Perfect Score On Human Rights Campaign Foundation's Corporate Equality Index 11/18/2015 2:57:44 PM
Boehringer Ingelheim Release: Time Is Of The Essence For Millions Living With "Neglected" Lung Disease:Your Time Campaign Calls For Earlier Action In COPD 11/17/2015 12:33:22 PM
Boehringer Ingelheim Release: New Analyses Further Add To The Efficacy And Safety Profile Of OFEV (nintedanib) In Idiopathic Pulmonary Fibrosis (IPF) 11/13/2015 7:33:12 AM
Boehringer Ingelheim Hacks Its R&D Budget to $11.8 Billion and Turns Focus on Collaborations Instead 11/12/2015 5:41:18 AM
Boehringer Ingelheim Will Invest 11 Billion Euros In Research And Development In The Next Five Years To Accelerate The Discovery Of Next Generation Medical Breakthroughs 11/11/2015 11:23:06 AM
Boehringer Ingelheim Release: Real-World Analysis Of More Than 44,000 Patients Reinforces Safety And Effectiveness Of Pradaxa In Routine Clinical Care 11/10/2015 12:40:25 PM